Based on our findings, targeted therapy including PI3K/Akt/mTOR pathway inhibitors, which is currently in clinical testing, may be potential treatment options for rare cases of apocrine-eccrine carcinomas. The gene discussed is AKT1; the disease is eccrine carcinoma.